Patients | 855 | 271 (31.7) | 251 (29.4) | 333 (38.9) | |
Females | 546 (63.9) | 187 (69.3) | 165 (65.7) | 194 (58.3) | 0.02 |
Age years | 48.6±15.6 | 50.4±15.7 | 47.4±15.2 | 48.1±15.8 | 0.08 |
Caucasian origin | 686 (81.8) | 210 (79.5) | 210 (84.7) | 266 (81.3) | 0.32 |
Other origin | 153 (18.2) | 54 (20.5) | 38 (15.3) | 61 (18.7) | 0.32 |
BMI kg·m−2 all patients | 27.1±6.1 | 26.9±5.9 | 28.2±6.8 | 26.5±5.6 | 0.002 |
Age of asthma onset years | 24.0±18.5 | 23.7±18.0 | 20.9±18.0 | 26.7±18.9 | 0.0008 |
Late asthma onset (>30 years) | 285 (33.9) | 88 (33.2) | 73 (29.4) | 124 (37.7) | 0.12 |
Asthma duration years | 24.7±17.5 | 27.0±19.2 | 26.5±16.8 | 21.4±16.1 | <0.0001 |
Asthma severity | | | | | |
Mild/moderate asthma (GINA 1–3) | 320 (38.6) | 109 (41.4) | 114 (46.3) | 97 (30.2) | 0.0002 |
Severe asthma (GINA 4–5) | 510 (61.4) | 154 (58.6) | 132 (53.7) | 224 (69.8) | 0.0002 |
Biological characteristics | | | | | |
Total serum IgE IU·mL−1 | 181 (67–457) | 101 (39–314) | 175 (66–389) | 255 (99–609) | <0.0001 |
With history of atopy | 487 (87.6) | 147 (85.5) | 157 (91.3) | 183 (86.3) | 0.21 |
Respiratory function | | | | | |
Pre-bronchodilator FEV1 % pred | 77.6±23.0 | 80.9±25.0 | 78.7±22.3 | 74.1±21.4 | 0.002 |
Post-bronchodilator FEV1 % pred | 80.7±31.4 | 83.4±24.1 | 83.8±45.1 | 76.6±22.3 | 0.05 |
Pre-bronchodilator FEV1 L | 2.28±0.91 | 2.31±0.90 | 2.33±0.91 | 2.23±0.90 | 0.34 |
Post-bronchodilator FEV1 L | 2.36±0.90 | 2.35±0.93 | 2.41±0.90 | 2.34±0.87 | 0.70 |
With post-bronchodilator FEV1 <70% pred | 168 (33.9) | 40 (28.4) | 47 (32.0) | 81 (38.9) | 0.11 |
Pre-bronchodilator FEV1/FVC % pred | 67.6±14.1 | 69.6±14.6 | 67.4±14.3 | 66.1±13.4 | 0.01 |
Reversibility to β2-agonists % | 9.3±14.8 | 7.4±14.4 | 8.7±13.2 | 11.2±15.9 | 0.02 |
Reversibility to β2-agonists mL | 169±263 | 140±294 | 154±245 | 200±249 | 0.04 |
With reversibility >12% and >200 mL | 165 (25.1) | 33 (16.9) | 46 (23.7) | 86 (32.0) | 0.001 |
Hospitalisations and treatments | | | | | |
Hospitalisations for asthma during lifetime n | 3.74±9.62 | 3.99±9.41 | 3.84±10.51 | 3.47±9.10 | 0.80 |
Hospitalisation for asthma in the past year | 196 (23.3) | 71 (26.7) | 49 (20.0) | 76 (23.1) | 0.21 |
Visits to emergency department in the past year | 404 (47.6) | 131 (48.9) | 106 (42.6) | 167 (50.5) | 0.16 |
Hospitalisation in ICU during lifetime | 185 (21.9) | 64 (23.9) | 53 (21.5) | 68 (20.5) | 0.61 |
With severe exacerbation in the past year | 569 (67.4) | 185 (69.0) | 149 (60.1) | 235 (71.7) | 0.02 |
OCS bursts in the past year n | 4.1±10.6 | 4.9±14.0 | 2.7±6.9 | 4.4±9.6 | 0.05 |
On maintenance use of OCS | 54 (6.4) | 20 (7.5) | 9 (3.6) | 25 (7.7) | 0.10 |
Dose of OCS mg per day | 21.7±17.8 | 26.0±20.0 | 22.4±16.8 | 18.1±16.1 | 0.34 |
Asthma control | | | | | |
Optimal asthma control | 195 (23.4) | 66 (24.9) | 72 (29.4) | 57 (17.6) | 0.002 |
Suboptimal asthma control | 229 (27.5) | 85 (32.1) | 62 (25.3) | 82 (25.4) | 0.002 |
Unacceptable asthma control | 409 (49.1) | 114 (43.0) | 111 (45.3) | 184 (57.0) | 0.002 |
ACQ score | 1.99±1.52 | 2.04±1.55 | 1.81±1.51 | 2.10±1.49 | 0.17 |